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Abstract
Aims/hypothesis Glucagon-like peptide 1 (GLP-1) is a gut
hormone used in the treatment of type 2 diabetes mellitus.
There is emerging evidence that GLP-1 has anti-inflammatory
activity in humans, with murine studies suggesting an effect
on macrophage polarisation. We hypothesised that GLP-1
analogue therapy in individuals with type 2 diabetes mellitus
would affect the inflammatory macrophage molecule soluble
CD163 (sCD163) and adipocytokine profile.
Methods We studied ten obese type 2 diabetes mellitus
patients starting GLP-1 analogue therapy at a hospital-based
diabetes service. We investigated levels of sCD163, TNF-α,
IL-1β, IL-6, adiponectin and leptin by ELISA, before and
after 8 weeks of GLP-1 analogue therapy.
Results GLP-1 analogue therapy reduced levels of the inflam-
matory macrophage activation molecule sCD163 (220 ng/ml
vs 171 ng/ml, p <0.001). This occurred independent of changes
in body weight, fructosamine and HbA1c. GLP-1 analogue
therapy was associated with a decrease in levels of the inflam-
matory cytokines TNF-α (264 vs 149 pg/ml, p <0.05), IL-1β
(2,919 vs 748 pg/ml, p <0.05) and IL-6 (1,379 vs 461 pg/ml
p <0.05) and an increase in levels of the anti-inflammatory
adipokine adiponectin (4,480 vs 6,290 pg/ml, p <0.002).
Conclusions/interpretation In individuals with type 2 diabe-
tes mellitus, GLP-1 analogue therapy reduces the frequency of
inflammatory macrophages. This effect is not dependent on
the glycaemic or body weight effects of GLP-1.
Keywords GLP-1 . Inflammation .Macrophage . Obesity
Abbreviations used
GLP-1 Glucagon-like peptide 1
iNKT Invariant natural killer T
PBMC Peripheral blood mononuclear cell
sCD163 Soluble CD163
Introduction
Chronic inflammation is a major contributor to the insulin
resistance that underpins obesity and type 2 diabetes. Macro-
phages play a distinct role in obesity-induced insulin-
resistance, driving adipose tissue inflammation [1]. In healthy
individuals, macrophages are regulatory M2 cells producing
the anti-inflammatory cytokine IL-10. In obesity, macro-
phages are polarised to the M1 inflammatory phenotype,
producing the proinflammatory cytokine IL-1β [2]. As
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macrophages become proinflammatory, removal of the
haptoglobin–haemoglobin receptor CD163 becomes upregu-
lated and is measurable as soluble CD163 (sCD163). sCD163
is strongly associated with insulin resistance independently of
inflammatorymarkers such as TNF-α [3]. The gastrointestinal
tract, its microbiome and gut hormones are increasingly
recognised as playing a key role in the crosstalk between
adipose tissue, immune cells and metabolic processes [4].
Glucagon-like peptide 1 (GLP-1) is a gastrointestinal peptide
hormone postprandially released by intestinal L cells. GLP-1
analogues and GLP-1 receptor agonists, are now used in the
management of type 2 diabetes. There is a growing body of
literature describing the extra-pancreatic effects of GLP-1,
including an emerging role in inflammation and regulation
of macrophages [5–8]. We previously observed changes in
invariant natural killer T (iNKT) cell number and function in
obese diabetic patients following GLP-1 analogue therapy [9].
The iNKT cell is a key regulator of macrophage function and
adipose tissue biology [10]. We therefore investigated the
effect of GLP-1 analogue therapy on macrophage-driven
inflammation and circulating adipocytokines, in a cohort
of ten subjects with type 2 diabetes.
Methods
Ethics statement and participants St Vincent’s University
Hospital Medical Research and Ethics Committee approved
this study. Written informed consent was obtained from every
participant prior to the start of any research activities. We en-
rolled ten participants with type 2 diabetes who were due
to commence GLP-1 analogue therapy for clinical indica-
tions (Table 1). All patients were on stable doses of oral
hypoglycaemic medications and their weight had been
stable for 4 weeks before the study. The dosages of statins
and other drugs were not changed during the study. Each
participant self-administered liraglutide by subcutaneous
injection at a dosage of 0.6 mg once daily for 2 weeks and
then 1.2 mg once daily thereafter. Before and after 8 weeks
of therapy, the research participants attended for a visit in
the early morning after an overnight fast. We recorded
reported adherence to treatment and weight and obtained a
venous blood sample. The sampled blood was used to
determine metabolic status and to assess peripheral blood
mononuclear cell (PBMC) function and serum analytes. A
cohort of age- and sex-matched lean, non-diabetic controls
were also recruited as comparators and experimental controls.
Human blood preparations Human PBMCs were prepared
by density gradient centrifugation over LymphoPrep
(Nycomed, Oslo, Norway) at 400 g for 25 min. Cells were
then washed twice with HBSS supplemented with HEPES
buffer solution (Invitrogen Life Technologies, Dublin,
Ireland) and antibiotics. Cell pellets were re-suspended in
1 ml of RPMI 1640 medium and cell yields and viability were
assessed by ethidium bromide–acridine orange staining.
Analysis of cytokine and sCD163 Patient PBMCs were stim-
ulated with phorbol myristate acetate (PMA) (10 ng/ml) and
ionomycin (1 μg/ml), or lipopolysaccharide (LPS) (10 ng/ml)
or media alone. After 24 h, supernatant concentrations of
IL-1β, TNF-α and IL-6 were determined by ELISA
(Biolegend, San Diego, CA, USA). sCD163 was measured
in the serum of patients using a quantikine ELISA kit (R&D
Systems, Abingdon, UK).
THP-1-derived macrophages Macrophages were derived
from the monocytic THP-1 cell line by stimulating with
PMA (10 ng/ml) for 24 h. Macrophages were polarised by
culturing with either IFN-γ (M1 phenotype) or IL-4 (M2
phenotype) during differentiation. The cells were then stimu-
lated with LPS in the absence or presence of GLP-1 analogue
for 24 h, and the cells’ supernatants assessed for cytokine
secretion by ELISA.
Statistical analysis All statistical analyses were performed
with Prism version 6.0 software (Graphpad, San Diego, CA,
USA). Data are presented as mean ± SEM or median with
range in parentheses. The groups were compared using Student’s
t test or Mann–Whitney U test, as appropriate. Correlation
analysis was performed using Spearman’s rank correlation test.
A p value <0.05 was considered statistically significant.
Results
The clinical characteristics of the ten type 2 diabetes patients
are presented in Table 1. HbA1c, weight and fructosamine did
improve in some patients after 8 weeks of GLP-1 analogue
Table 1 Clinical characteristics of the participants with type 2 diabetes
mellitus commencing GLP-1 analogue (n =10)
Baseline Post-GLP-1 p value
Gender 3 women, 7 men – –
Age (years) 54.6±8.4 – –
Diabetes duration (years) 7.7±5.4 – –
Weight (kg) 128 (83–166) 125 (80–165) 0.9
HbA1c
mmol/mol 72 (45–104) 63 (42–86) 0.33
% 8.7 (6.3–11.7) 7.9 (6.0–9.7) 0.05
Fructosamine (μmol/l) 299 (432–211) 266 (347–210) 0.07
sCD163 (ng/ml) 226 (187–260) 176 (115–229) 0.0006
Data are expressed as mean ± SD or median values with range in
parentheses
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therapy, although the median change for the group was not
statistically significant (Table 1).
GLP-1 analogue therapy decreases proinflammatory macro-
phages and reduces inflammation in type 2 diabetes Type 2
diabetic patients have significantly higher levels of the inflam-
matory macrophage associated-molecule sCD163 compared
with a cohort of age and sex matched non-obese controls
(Fig. 1a). There was a significant decrease in the levels of
sCD163 post GLP-1 treatment (220 ng/ml vs 171 ng/ml,
p <0.001), indicating a reduction in the number of inflamma-
tory macrophages (Fig. 1b). The change in sCD163 levels
showed no correlation with change in HbA1c (r =−0.09,
p =0.8), change in weight (r =−0.26, p =0.46) or change in
fructosamine (r =−0.05, p =0.9) (Fig. 1c–e). One of the largest
reductions in sCD163 levels (−83 ng/ml) occurred in a patient
who had no clinically significant change in weight (−1.2 kg)
or HbA1c level, +2 mmol/mol (+0.2%). Conversely, the
smallest reduction in sCD163 levels (−19 ng/ml) occurred in
a patient with a decrease in HbA1c of 20 mmol/mol (−1.9%).
GLP-1 analogue therapy was associated with a reduction in
PBMC production of the proinflammatory cytokines TNF-α
(264 vs 149 pg/ml, p <0.05), IL-1β (2,919 vs 748 pg/ml,
p <0.05) and IL-6 (1,379 vs 461 pg/ml p <0.05) (Fig. 1f–h).
GLP-1 analogue therapy resulted in an increase in serum
adiponectin (4,480 vs 6,290 pg/ml, p <0.002) and a trend
towards a decrease in serum leptin (5,250 vs 4,054 pg/ml
p =0.1), consistent with a reduction in adipose inflammation
(Fig. 1i, j).
GLP-1 analogue therapy modulated macrophage function
in vitro, resulting in decreased IL-1β production (380 pg/ml
vs 267 pg/ml, p <0.001) by M1 macrophages and increased
IL-10 (15 pg/ml vs 33 pg/ml, p <0.001) production by M2
macrophages (Fig. 1k, l).
Discussion
This work indicates that, in individuals with type 2 diabetes
mellitus, GLP-1 analogue therapy causes a reduction in the
levels of the inflammatory macrophage-derived sCD163. The
reduction in sCD163 showed no correlation with the change in
HbA1c, fructosamine or body weight. This supports a direct
effect of GLP-1 on innate immune cell function.
Fig. 1 GLP-1 analogue therapy
decreases sCD163 levels in type 2
diabetes (T2DM) and alters the
adipocytokine profile. (a) Serum
sCD163 levels in cohort of
T2DM participants (n=10)
compared with lean, healthy
controls (n =5). (b) Serum
sCD163 levels in cohort of
T2DM participants before and
after 8 weeks GLP-1 analogue
therapy (n =10). Correlation plots
comparing change in (Δ) sCD163
vsΔ weight (r =−0.26, p =0.46)
(c), Δ HbA1c (r =−0.09, p =0.8)
(d) or Δ fructosamine (r=−0.05,
p =0.9) (e) after 8 weeks of GLP-
1 analogue therapy. Production of
TNF-α (f), IL-1β (g) or IL-6 (h)
by PBMCs isolated from T2DM
participants (n=10) before and
after 8 weeks of GLP-1 analogue
therapy. Serum leptin (i) or
adiponectin (j) levels in cohort of
T2DM participants before and
after 8 weeks of GLP-1 analogue
therapy (n =10). Effect of GLP-1
analogue treatment on levels of
IL-1β (k) and IL-10 (l) produced
by THP-1-derived macrophages
in vitro (n=3). *p <0.05,
**p <0.01, ***p<0.001
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We have previously demonstrated that GLP-1 regulates
invariant natural killer T (iNKT) cells, which are a rare subset
of innate T cells involved in regulating macrophage and
adipose tissue biology [10]. In humans, GLP-1 analogue
therapy increases circulating iNKT cell frequency and acti-
vates anti-inflammatory pathways within the iNKT cell. Diet-
induced obesity results in the loss of iNKT cells from murine
peripheral blood and adipose tissue, which in turn results in
the switching of macrophages from the M2 state to the proin-
flammatory M1 state. We therefore studied sCD163 as a
marker of inflammatory macrophages to establish the effect
of GLP-1 analogue therapy on macrophage polarisation in
humans. Our finding that GLP-1 decreases sCD163 levels in
patients is in line with a recent study of GLP-1 overexpression
in obese mice that resulted in increased thermogenesis and
polarisation of macrophages from the M1 to the M2
phenotype [7]. While iNKT cell instruction of macrophage
activation could account for this, our in vitro data demonstrate
a direct effect of GLP-1 on macrophage polarisation.
Chronic inflammation driven by altered cytokine produc-
tion plays a central role in the insulin resistance that underpins
obesity and type 2 diabetes. Inflammatory macrophages are a
major source of proinflammatory cytokines such as TNF-α
and IL-1β. These cytokines lead to increased insulin resis-
tance via a number of mechanisms, including activation of
inflammatory pathways, serine phosphorylation of the insulin
receptor and insulin receptor substrate 1, and increased serum
and hepatic triacylglycerol levels [11, 12]. We provide
evidence for a decrease in PBMC production of the inflamma-
tory cytokines TNF-α, IL-1β and IL-6 in patients treated with
GLP-1 analogue. This may contribute to the improved insulin
sensitivity observed in response to GLP-1 analogue therapy.
Our finding that adiponectin levels were significantly in-
creased in patients treated with GLP-1 suggests an effect on
adipose tissue inflammation. As discussed earlier, adipose
tissue is a major contributor to obesity-driven inflammation,
with infiltrating cells such as macrophages and Tcells shaping
the cytokine profile; however, adipocytes themselves play a
role in this through the production of adipokines such as
adiponectin and leptin. Adiponectin is exclusively produced
by adipocytes and has anti-inflammatory and insulin-
sensitising properties. In healthy, lean adipose tissue,
adiponectin is abundant, but in inflamed obese adipose tissue,
adiponectin secretion is reduced and leptin is increased.
This study does not address whether the effect of GLP-1 on
adipocyte tissue inflammation is direct, is immune cell medi-
ated or occurs as a result of metabolic change, and highlights
the lack of a control group as a weakness of this study.
However, our in vitro work presented here, showing a
decrease in IL-1β production by M1 macrophages and an
increase in IL-10 production by M2 macrophages in response
to GLP-1, supports a direct immune effect. This is consistent
with our findings in vivo and the findings of Lee et al in
murine studies [7] and indicates an effect of GLP-1 at a
number of levels within the inflammatory cascade.
In summary, our findings demonstrate that GLP-1 analogue
therapy has effects on innate immune cell-driven inflammation
and adipose tissue function.
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